Investors struggle to assess technical viability in alt-protein.
Technical due diligence reports that evaluate scientific claims.
Sell subscription access to venture capital firms.
Launch with one in-depth analysis before scaling.
Risk: Requires rare scientific-commercial crossover expertise.